Advances With Erdafitinib Exemplify the Push For Precision Medicine in Urothelial Cancer
Petros Grivas, MD, PhD, expands on key updates in the second-line management of urothelial cancer.
Source: onclive.com
Genitourinary Cancers Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Genitourinary Cancers Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Genitourinary Cancers Program Today - Breaking & Trending Today
Dr Grivas on Frontline Treatment Options in Metastatic RCC
Petros Grivas, MD, PhD, discusses frontline treatment options for patients with metastatic renal cell carcinoma.
Source: onclive.com
Grivas Expands on Key Data From the 2023 ESMO Congress in Urothelial Cancer
Petros Grivas, MD, PhD, spotlights key advancements and research in urothelial cancer reported at the 2023 ESMO Congress, detailing findings from the phase 3 CheckMate 901, EV-302/KEYNOTE-A39, and THOR trials.
Source: onclive.com
Grivas Expands on Therapeutic Developments and Future Research Directions in GU Cancers
Petros Grivas, MD, PhD, discusses the role of single-agent and combination PARP inhibitor regimens in prostate cancer, as well as the importance of genetic testing in this setting, the role of adjuvant regimens in resected renal cell carcinoma, and more.
Source: onclive.com
Dr Grivas on Key Data From the CheckMate 901 Trial in Urothelial Cancer
Petros Grivas, MD, PhD, discusses outcomes associated with the phase 3 CheckMate 901 trial in metastatic or unresectable urothelial carcinoma, highlighting the importance of these data.
Source: onclive.com